Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alzheimer’s discovery could lead to new therapies
In Alzheimer’s disease, two kinds of abnormal structures accumulate in the brain: amyloid plaques and neurofibrillary tangles. The plaques contain fibrils that are made from protein fragments called
In Alzheimer’s disease, two kinds of abnormal structures accumulate in the brain: amyloid plaques and neurofibrillary tangles. The plaques contain fibrils that are made from protein fragments called
Viprovex showed protection from infection by Bacillis anthracis and influenza A viruses. Studies looking at potential mechanisms have examined cellular components of the host immune system and have
The program assessed the results of three clinical trials showing that overall upper gastrointestinal (GI) events such as bleeding, perforation, obstruction or ulcer were significantly less common with
The target population for the study is patients with durable viral suppression from highly active antiretroviral therapy. AGS-004 is a personalized RNA-loaded dendritic cell-based immunotherapy that is designed
Pennsaid is a topical non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis and is currently approved for sale in Canada and several European countries. In a
As was previously reported the drug known as 4975 demonstrated pain reduction at all pre-specified time intervals in the study. New data from this study shows a trend
GSK plans to establish three Centers for Excellence in Drug Discovery (CEDDs) in an effort to increase productivity. These will be in addition to eight existing centers. These
The companies said that preliminary data from the trial of the drug GS 9132, did demonstrate antiviral activity and met the goal of the trial. This validates the
This new indication is based on results of a large phase III trial which showed prolonged progression-free survival. Sutent was originally approved in January 2006 for the treatment
Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. Current treatment modalities include physical interventions such as cryosurgery,